We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FAB Fusion Antibodies Plc

0.15 (4.11%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.15 4.11% 3.80 1,463,194 14:00:28
Bid Price Offer Price High Price Low Price Open Price
3.70 3.90 3.80 3.65 3.65
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0272 -1.40 3.62M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:19 O 25 3.90 GBX

Fusion Antibodies (FAB) Latest News

Fusion Antibodies (FAB) Discussions and Chat

Fusion Antibodies Forums and Chat

Date Time Title Posts
27/5/202421:07☆ Fusion Antibodies: from discovery to Clinical supply ☆3,899
28/11/202316:25NEW FAB Fusion Antibodies The Next AVCT64
18/9/202015:23Fusion Antibody II51
08/2/201221:34Fabio Capello Resigns.......9

Add a New Thread

Fusion Antibodies (FAB) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Fusion Antibodies (FAB) Top Chat Posts

Top Posts
Posted at 27/5/2024 09:20 by Fusion Antibodies Daily Update
Fusion Antibodies Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 3.65p.
Fusion Antibodies currently has 95,365,564 shares in issue. The market capitalisation of Fusion Antibodies is £3,623,891.
Fusion Antibodies has a price to earnings ratio (PE ratio) of -1.40.
This morning FAB shares opened at 3.65p
Posted at 23/5/2024 11:51 by paulisi
I do see signs of potential.New contracts are coming in, even if they are small.However, if this share price is to jump it needs:At least one of the contracts to commercialise and generate revenues via royaltiesMore contracts, to avoid having to ask the market for more cash.At the moment, it is a very speculative share.
Posted at 23/5/2024 08:20 by citys2874
Yes great news out today for FAB and IXI should both rally
Posted at 30/4/2024 16:35 by jaknife

"On the contrary that was a strong update."

Is that why the share price crashed 10% on the day? Because it was a "strong update"?

What in particular did you think was "strong"? Was it the revenue news?

"Unaudited revenues for FY2024 of £1.14m (FY2023: £2.90m)"

^^ Down over 60%!

"Significant increase in sales pipeline opportunities during H2 FY2024, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent. of total FY2024 unaudited revenues"

^^ A trivial sales pipeline that's less than my local sandwich shop!

"Cash position as at 31 March 2024 of £1.2m (31 March 2023: £0.2m)"

^^ They've already started to burn through the £1.37m of funds that were raised in Feb!

At best we're twelves months away from the next fund raise. At worst your fellow shareholders will finally cotton on that this is a total basket case that's not worth supporting.

Posted at 30/4/2024 13:47 by bobaxe1
On the contrary that was a strong update. The company has raised well above the current share price at 5.66 . Cash is great going forward had our best month earnings in years delayed earnings will arrive. So just sitting oversold with the usual trolls giving their pennies worth
Posted at 27/2/2024 10:31 by troutisout
"Fusion Antibodies (FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announced it has received a first purchase order under the master services agreement (MSA) with a leading diagnostics company details of which were announced on 14 February 2024. FAB said reaching this agreement with a world class diagnostics provider positively reinforces the value to the wider commercial world of Fusion Antibodies’ technologies and capabilities. In this case it is the generation of antibodies in diagnostics products.

Comment: It could be argued that fundamentally FAB is now on track as a recovery situation, with the purchase order and recent funding. Only a rise in the share price is missing."
Posted at 14/2/2024 13:07 by dreamtwister
careful jock the share price will dip below the price of the placings.
Posted at 23/1/2024 16:30 by jaknife
I have no particular interest in FAB anymore, it's too small a company. But I would be interested to see any calculations that anyone has done of (a) what FAB's current monthly cash burn is, and (b) therefore what FAB's current cash position is.

Do people routinely do these sorts of calculations before investing?

Posted at 08/12/2023 10:37 by jaknife

Look back at the chart for FAB.

Can you see that massive fall in the share price in May? From c. 40p to about 6p?

That coincided with this RNS when the 5p placing was announced:

It's unlikely that the next placing will have such a huge discount. But it's also unlikely that FAB will make it through 2024 without yet another placing. If you disagree then buy, it's your choice and the decision is solely down to you.

Posted at 06/12/2023 14:31 by daniel
Don't listen to Jaknife. He works for certain brokerage firms seeking to undermine companies by depressing the share prices; in the hope of getting cheap shares after front-selling. Check out his history with many companies. He is a scammer that manipulates unseasoned PI's.

You can see him targeting fundraising but totally ignoring the OptiMal Collaboration agreement. That's the usual pattern. But you wander where the donkey had been when the share price was much higher.

I am looking to invest in this company, but his presence is depressant to the share price.
Posted at 20/5/2023 10:40 by hedgehog 100
JakNife 6 Apr '23 - 18:29 - 3279 of 3333 0.010000 4 1
"Here's another hugely dilutive placing that's been agreed in the sector:

It's a chunky raise but at 1p it's an 84% discount to the closing price before it was previously suspended.
All arrows point to a fund raise for FAB that materially dilutes current shareholders.

Well done to JakNife ... his AGY example was even the precise % discount as FAB's.

dave454519 May '23 - 10:15 - 3283 of 3333 0 1 1
"Bloody hell that is savage.
At least they did not have the nerve to say they were "pleased" to announce"

Not in yesterday's first RNS Dave, but they still managed to get in two 'pleased to say/announce' yesterday:-

19/05/2023 10:00 UK Regulatory (RNS & others) Fusion Antibodies PLC Placing, Subscription and Retail Offer LSE:FAB Fusion Antibodies Plc
" ... Fusion Antibodies CEO, Adrian Kinkaid said : "We are pleased to say that we have been able to raise funds in an extremely challenging market, ..." ..."

19/05/2023 10:01 UK Regulatory (RNS & others) Fusion Antibodies PLC REX Retail Offer LSE:FAB Fusion Antibodies Plc
"Fusion Antibodies plc (AIM: FAB) is pleased to announce a retail offer via REX (the "REX Retail Offer") of ordinary shares ("Ordinary Shares") of 4 pence each in the capital of the Company (the "REX Retail Offer Shares")
... The issue price of the Placing Shares and Subscription Shares is 5 pence (the "Issue Price"). The price of the REX Retail Offer Shares is equal to the Issue Price. ..."

volsung 19 May '23 - 10:20 - 3288 of 3333 0 0 1
"Not the best Belfast share"

No, but the tiny number of London-listed N.I. shares includes former 15-bagger Kainos (KNOS) (still currently an 8.8-bagger from its 2015 IPO price of 139p); and FD Technologies (FDP) - currently a 37.6-bagger from its 2002 IPO price of 50p.

See the "Rockpool Acquisitions (ROC)" thread for details (it's a Northern Ireland shell company currently arranging a RTO):-
Fusion Antibodies share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock